Na+/H+ exchanger regulatory factor 1 overexpression suppresses the malignant phenotype of MIAPaCa-2 pancreatic adenocarcinoma cells by downregulating Akt phosphorylation
暂无分享,去创建一个
[1] Xueran Chen,et al. A novel splice variant of supervillin, SV5, promotes carcinoma cell proliferation and cell migration. , 2017, Biochemical and biophysical research communications.
[2] N. Copeland,et al. KRAS-related proteins in pancreatic cancer. , 2016, Pharmacology & therapeutics.
[3] Stephen L. Abrams,et al. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. , 2016, Biochimica et biophysica acta.
[4] G. Lesinski,et al. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities , 2016, Molecular Cancer Therapeutics.
[5] D. Goldstein,et al. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. , 2016, Anticancer research.
[6] Soon-Sun Hong,et al. HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer , 2016, Oncotarget.
[7] Yue Zhang,et al. EBP50 interacts with EGFR and regulates EGFR signaling to affect the prognosis of cervical cancer patients. , 2016, International journal of oncology.
[8] E. Miyoshi,et al. Application of glycoscience to the early detection of pancreatic cancer , 2016, Cancer science.
[9] Yuan-yuan Zhu,et al. MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway , 2016, OncoTargets and therapy.
[10] Namrata Vijayvergia,et al. Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? , 2016, Journal of gastrointestinal oncology.
[11] M. Georgescu,et al. NHERF1/EBP50 Suppresses Wnt-β-Catenin Pathway–Driven Intestinal Neoplasia1 , 2016, Neoplasia.
[12] Yan Wang,et al. NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer , 2016, Oncotarget.
[13] Q. Ma,et al. Targeting of NHERF1 through RNA interference inhibits the proliferation and migration of metastatic prostate cancer cells. , 2016, Oncology letters.
[14] A. Paradiso,et al. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells. , 2015, International journal of oncology.
[15] Hongli Li,et al. EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway , 2014, Medical Oncology.
[16] Q. Ma,et al. Breast cancer‐derived K172N, D301V mutations abolish Na+/H+ exchanger regulatory factor 1 inhibition of platelet‐derived growth factor receptor signaling , 2013, FEBS letters.
[17] Y. Li,et al. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation , 2012, Amino Acids.
[18] D. Lallemand,et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin , 2007, The Journal of cell biology.
[19] M. James,et al. A NHERF binding site links the βPDGFR to the cytoskeleton and regulates cell spreading and migration , 2004, Journal of Cell Science.
[20] Huiqi Pan,et al. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. , 2003, International journal of oncology.
[21] S. Hirohashi,et al. EBP50, a β‐catenin–associating protein, enhances Wnt signaling and is over‐expressed in hepatocellular carcinoma , 2003, Hepatology.